Renee Poels
Amsterdam, NH, Netherlands
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 10 publications
Combining a CAR and a chimeric costimulatory receptor enhances T cell sensitivity to low antigen density and promotes persistence.
Journal: Science translational medicine
Published: December 08, 2021
Preclinical Evaluation of Invariant Natural Killer T Cells Modified with CD38 or BCMA Chimeric Antigen Receptors for Multiple Myeloma.
Journal: International journal of molecular sciences
Published: December 16, 2020
Bone Marrow Mesenchymal Stromal Cell-mediated Resistance in Multiple Myeloma Against NK Cells can be Overcome by Introduction of CD38-CAR or TRAIL-variant.
Journal: HemaSphere
Published: December 14, 2020
CD38-specific Chimeric Antigen Receptor Expressing Natural Killer KHYG-1 Cells: A Proof of Concept for an "Off the Shelf" Therapy for Multiple Myeloma.
Journal: HemaSphere
Published: December 07, 2020
Bone Marrow Mesenchymal Stromal Cells Can Render Multiple Myeloma Cells Resistant to Cytotoxic Machinery of CAR T Cells through Inhibition of Apoptosis.
Journal: Clinical cancer research : an official journal of the American Association for Cancer Research
Published: June 09, 2020
Combined CD28 and 4-1BB Costimulation Potentiates Affinity-tuned Chimeric Antigen Receptor-engineered T Cells.
Journal: Clinical cancer research : an official journal of the American Association for Cancer Research
Published: August 06, 2018
Feasibility of controlling CD38-CAR T cell activity with a Tet-on inducible CAR design.
Journal: PloS one
Published: November 17, 2017
A Rational Strategy for Reducing On-Target Off-Tumor Effects of CD38-Chimeric Antigen Receptors by Affinity Optimization.
Journal: Molecular therapy : the journal of the American Society of Gene Therapy
Published: December 21, 2016
Showing 1-10 of 10
Last Updated: 09/26/2026